Before we move on to the Society for Immunotherapy of Cancer (SITC) meeting later this week, it’s time to wrap up the exciting AACR-NCI-EORTC molecular targets conference, which along with the CRI-CIMT-EATI-AACR international cancer immunotherapy conference in Mainz, have been my two favourite oncology meetings of the year so far.
Who would have predicted that back in January?
A scoot around the narrow #Targets17 poster hall…
It would be hard not to close out coverage without a popular Gems from the Poster Halls post.
Typically, we have focused this theme from cancer conferences around the following:
- A new target
- An interesting molecule
- Intriguing basic or translational science of note
- A particular tumour type
- Insightful sentiments from thought leaders
In this latest version, we have examples of each. We also have my favourite quote and discussion from the meeting, which perhaps not surprisingly, comes from a CAR T cell therapy discussion.
To learn more insights on the latest Gems from the Poster Hall series, subscribers can log-in or you can click to gain access to BSB Premium Content.
After regularly reporting here at BSB on several readouts in terms of antibodies and CARs since ASH last year, it’s reasonable to conclude now that there has been growing interest in BCMA–APRIL as a target in multiple myeloma (MM). The CAR T cell therapies have generally focused on BCMA or BCMA-TACI as a target, while antibody approaches such as Aduro’s, BION–1301, target APRIL.
T cells attacking a cancer cell
These new therapies have all been either preclinical in nature or preliminary phase 1 studies in a very limited number of patients, meaning that the best we can characterise them is that old reliable chestnut, ‘promising but early’… to do otherwise would be rather extravagant and hopeful at best.
Given the data from several CAR T cell therapy studies were being presented at two meetings on two separate continents only a few days apart, it makes sense to review them as a whole.
It’s therefore time for a detailed update, including a review of the differences in the key studies, a look at where we are now, as well as tips on what to look for going forward.
Subscribers can log-in to learn more insights
The AACR Poster Halls get packed quickly!
It’s time to change direction and take a look at some of the Gems from the Poster Halls at the recent American Association for Cancer Research (AACR) meeting.
One particular abstract that looked interesting related to the Aduro compound, BION–1301, which is a monoclonal antibody targeting the B cell Maturation Antigen and its ligand, A Proliferation Inducing Ligand (BCMA-APRIL) in multiple myeloma.
Increasingly, there has been a lot of clinical interest in the BCMA target, but what about APRIL?
We spoke to one of the scientists involved in the research about this novel agent:
“It is very effective at abrogating the activity of APRIL and, in particular, in our models blocks the growth, survival, drug resistance, migration and adhesion of myeloma cells both in-vitro and in-vivo in our murine models. These models have been predictive for clinical activity of other novel targeted therapies including lenalidomide and bortezomib, and so we think targeting APRIL represents a very promising strategy.”
Sounds pretty good, right?
To learn more about what they had to say about this approach, subscribers can log-in or you can sign-up.